Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

VIRAL HEPATITIS IN 2020

Hepatitis C virus elimination: laying the foundation for achieving 2030 targets

Nature Reviews Gastroenterology & Hepatology volume 18, pages 91–92 (2021)Cite this article

Subjects

An Author Correction to this article was published on 05 January 2021

This article has been updated

The World Health Organization’s targets for hepatitis C elimination by 2030 are ambitious, but, in 2020, global leadership demonstrated by Egypt, innovative strategies to improve linkage to treatment for marginalized populations and the broadened capacity of direct-acting antiviral therapy have been promising for enhanced global elimination efforts.

Key advances

  • A massive national hepatitis C screening and treatment programme in Egypt has demonstrated the feasibility of major progress towards elimination in a high-prevalence lower–middle income country setting6.

  • A cluster-randomized trial in Scottish pharmacies found higher linkage to treatment for people on opiate agonist therapy using a pharmacist-led model of care compared with a conventional model of care7.

  • An ultra-short (7 day) antiviral regimen was highly effective (100%) for prevention of hepatitis C virus (HCV) infection in HCV-uninfected recipients of solid organ transplants from donors with HCV infection9.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Cascade of HCV care in Egypt.

Change history

  • 05 January 2021

    A Correction to this paper has been published: https://doi.org/10.1038/s41575-020-00407-z.

References

  1. Choo, Q. L. et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359–362 (1989).

    Article  CAS  Google Scholar 

  2. World Health Organization. Global health sector strategy on viral hepatitis 2016-2021 https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf;jsessionid=60A93ADD1A191FF6A0FA823314D24C43?sequence=1 (WHO, 2016).

  3. Naghavi, M. et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390, 1151–1210 (2017).

    Article  Google Scholar 

  4. World Health Organization. Global Hepatitis Report, 2017 https://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.pdf?sequence=1 (WHO, 2017).

  5. Dore, G. J. & Feld, J. J. Hepatitis C virus therapeutic development: in pursuit of “perfectovir”. Clin. Infect. Dis. 60, 1829–1836 (2015).

    Article  CAS  Google Scholar 

  6. Waked, I. et al. Screening and treatment program to eliminate hepatitis C in Egypt. N. Engl. J. Med. 382, 1166–1174 (2020).

    Article  Google Scholar 

  7. Radley, A. et al. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial. Lancet Gastroenterol. Hepatol. 5, 809–818 (2020).

    Article  Google Scholar 

  8. Durand, C. M. et al. The drug overdose epidemic and deceased-donor transplantation in the United States: a national registry study. Ann. Intern. Med. 168, 702–711 (2018).

    Article  Google Scholar 

  9. Feld, J. J. et al. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. Lancet Gastroenterol. Hepatol. 5, 649–657 (2020).

    Article  Google Scholar 

  10. Larney, S. et al. Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. Lancet Glob. Health 5, e1208–e1220 (2017).

    Article  Google Scholar 

Download references

Acknowledgements

The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. The content is solely the responsibility of the authors. G.J.D. is supported through a National Health and Medical Research Council Practioner Fellowship.

Author information

Authors and Affiliations

  1. Kirby Institute, UNSW Sydney, Sydney, New South Wales, Australia

    Gregory J. Dore & Sahar Bajis

Authors
  1. Gregory J. Dore
    View author publications

    Search author on:PubMed Google Scholar

  2. Sahar Bajis
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Gregory J. Dore.

Ethics declarations

Competing interests

G.J.D. is an advisory board member and receives honorarium from Gilead, Merck and Abbvie, has received research grant funding from Gilead, Merck and Abbvie, and travel sponsorship from Gilead, Merck and Abbvie. S.B. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dore, G.J., Bajis, S. Hepatitis C virus elimination: laying the foundation for achieving 2030 targets. Nat Rev Gastroenterol Hepatol 18, 91–92 (2021). https://doi.org/10.1038/s41575-020-00392-3

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41575-020-00392-3

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing